Genome & Company
B-8F Silicon Park, 35 Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13486
Consent to collection and use of personal information (Required)
Genome & Company (the ”Company”) regards the protection of personal information of our users very important, and complies with relevant laws, including the Personal Information Protection Act and the Act on Expansion of Dissemination and Promotion of Utilization of Information System. The Company hereby informs the purpose and method of using the personal information provided by our users through the Company’s website, and what measures are taken to protect the personal information. If the Company revises any of this Private Policy, it will be notified through the notices on the Company’s website (or individually notified).
The Company collects the following personal information to operate its Contact Service via the Company’s website (whereby the users can make general inquires, inquiry for business development, IR inquiry, media inquiry, etc.).
- Essential Information: name, e-mail address, phone number, organization, content of inquiry
- Collection method: The Company collects the personal information through the inquiries submitted via the Contact Bulletin Board on the Company’s website.
You have the right to refuse the ‘collection of essential information’ as well as the ‘collection of optional information’. If you refuse the collection of essential information, however, you may be restricted for using the Contact Service.
The following information may be automatically generated and collected in the process of using the website.
- IP Address, cookie, date and time of visit, records of service use
The Company uses the collected personal information for the following purposes.
- Personal verification, personal identification, delivery of inquiries and notification of results (answers and responses), etc. related to the use of Contact Service
In principle, the collected personal information is destroyed without any delay after achieving the purpose of collecting and using personal information. However, the Company may keep users’ information for a certain period of time as required by relevant laws.
- Retained information: personal information submitted with the inquiry, content of the inquiry, and ensuing responses
- Relevant Law: Act on the Consumer Protection in Electronic Commerce, etc.
- Retention Period: three years (records related to resolution of consumer complaints or disputes)
In principle, the information is destroyed without any delay after achieving the purpose of collecting and using personal information. The procedure and method of destruction are as follows.
The personal information submitted is transferred to a separate database (in case of paper, separate cabinet) after achieving the purpose and kept for a certain period of time according to the internal policy and other relevant laws, before it is destroyed. The personal information transferred to separate database shall not be used any other purposes other than for keeping in accordance with laws.
2) Destruction Method
Personal information saved in the form of electronic file shall be deleted by using technical method that cannot reproduce the records. Personal information printed in the paper shall be destroyed by shredding with a shredder or incinerating it.
In case users request the correction of any errors in personal information, we shall not use or provide the personal information until such correction is made. In addition, in case incorrect personal information is already provided to a third party, we will notify the third party the result of correction without delay.
The Company processes and destroys personal information at the request of users or their legal representatives in accordance with Section ‘3. Processing of Personal Information and Retention Period’ and Section ‘4. Destruction of Personal Information’, and such information shall not be opened or used for any other purposes.
The Company designates data protection officer and manager for managing personal information as follows to protect users’ personal information related to inquiries.
Data Protection Officer
Name: Seo Yeong-jin
Department: Business management
Data Protection Manager
Name: Seol Su-gi
Department: PR team
Position: Team Lead
You can submit to the personnel above any inquiries related to your personal information submitted to the Company while using our web service. The Company will quickly provide sufficient responses to your inquiries.
Please contact the below agencies if you need report or counseling for any infringement of personal data privacy.
- Personal Information Infringement Report Center (privacy.kisa.or.kr / 118 without area code)
- Personal Information Dispute Mediation Committee (kopico.go.kr / 1833-6972)
- Cyber Investigation Department, Supreme Prosecutor’s Office (www.spo.go.kr / 1301 without area code)
- Cyber Bureau of the National Police Agency (http://cyberbureau.police.go.kr / 182 without area code)
Based on its library of real-world clinical data, and multi-omics analysis capability, Genome & Company is active in researching of 1) microbiome therapeutics and consumer products and 2) novel target oncology therapeutics
Microbiome Research Center is a dedicated research unit for identifying microbiome therapeutic candidates. The research center has developed microbiome pipelines in variety of indications such as GEN-001 in immuno-oncology and the others in infertility and cancer associated rash.
The research center isolates live bacteria strains for the purpose of screening for variety of indications in medial unmet needs. The selected strains are then validated though identification of mechanism of action, in-vitro/in-invo efficacy studies and microbial process development prior to entering a clinical study.
New Drug Research Center validates novel targets to develop antibodies as a therapeutic candidate by using New Drug platform technology GNOCLE™. The novel targets identified by Genome & Company is found to be inhibiting immune cells (T cells) stronger than PD-L1 which is the best known immune checkpoint.
Development of antibodies for a such novel targets is expected to enhance the activation of immune cells (T cell) than existing immunotherapy. Genome & Company aims to provide new treatment to patients who are non-responsive or resistance to the existing immunotherapy
Research and development for new drug by Genome & Company is not only limited to antibody for novel immuno-oncology target, but also other innovative anti-cancer therapeutics in new modalities based on the novel targets discovered through GNOCLE™, our proprietary drug development platform.
Bioinformatics(BI) analysis identifies novel targets and its mechanism of action based on preclinical and clinical samples using multi-omics approach (genomics, transcriptomics, proteomics, metabolomics).
In addition, BI Team supports research and development activities by big-data analysis of animal and human specimen (faces, urine, blood, etc.) of variety of disease types (over 10,000 samples related to core diseases such as cancer, cancer associated rash, atopic dermatitis, dementia, infertility, and etc.).
Genome & Company’s drug R&D expertise is not only limited to research, but also to clinical development, regulatory affairs and intellectual property, to the entire drug development process.
Clinical Development is responsible for overall planning, designing, operation and quality management of a clinical study outcomes to advance a development pipeline to therapeutic candidate.
Clinical Development manages and supervises the operation of clinical studies and clinical collaborators including CROs and investigators under the compliance with domestic and overseas regulations (ICH guideline, Good Clinical Practice (GCP)).
RA/QA communicates and prepares documents to be submitted to respective regulatory agencies for the approval of investigational new drug(IND), new drug application(NDA), biological license application(BLA) and marketing authorization application(MAA).
Additionally, RA/QA is responsible for quality assurance and management of the drug development process in Genome & Company’s internal research centers as well as external CDMO (Contract Development Manufacturing Organization). Pharmacovigilance of the investigational medical product(IMP) for clinical studies are also with scope of the responsibility.
Intellectual Property (IP) is responsible in overseeing the legal proceedings of patent/trademark filing, registration and maintenance as well as defending the company IP against a litigation.
Working closely in collaboration with the research centers, IP sets up patent filling strategies that blends core drug discovery technology, target indications, and manufacturing processes to form an IP portfolio in protecting Genome & Company’s development pipeline effectively.
HR & Finance manages and supports employees so that they can focus on work and effectively make achievement in stable work environment and to coordinate management activities in each sector.
Human Resources plans and operates all process of using human resources from securing important human resources and fair evaluation and reward system to training and retirement, helping sustainable growth of the company. In addition, the department analyzes labor environment to establish suitable strategy.
Finance manages all financial information of the company and decides accounting task and tax policies conducted for consolidated accounting settlement of head office and domestic and overseas corporations and performs funding business of managing and executing financial work and cash flow to report taxes.
Legal Department manages legal risks and provides legal service (review contract, dispute management, legal advice, etc.) under domestic and overseas laws accompanied by management activities.
Business Development sets up a corporate strategy for discovering mid-to-long term growth drivers and open innovations/external partnerships as well as new business strategy for commercial execution and business expansion.
Healthcare Business Development(BD) establishes and strengthens global partnership while creating a strategic partner outreach to identify potential partners as well as negotiating for term sheet and definitive agreement to execute a deal. The deal type includes creating profit models such as licensing in/out and R&D collaboration through open innovations. Business Development also communicates for alliance management to ensure the partnership continues to excel with productive outcomes.
Consumer Business Development(BD) oversees new consumer product launches directly commercialized by Genome & Company. Genome & Company’s first consumer product, UIQ, a cosmetic brand is launched in January 2021. Consumer BD performs to bring commercial excellences from product planning, launching, branding and marketing/promotion of Genome & Company’s consumer brands. Please visit UIQ official website for more details.
Communication establishes internal and external communication strategy as well as risk management strategy for IR and PR activities.
IR (Investor Relations) is a corporate responsibility that covers finance, communication, and compliance with security laws to enable the most effective two-way communication among a company, financial community and other stakeholders.
As a part of the publicly traded company, IR at Genome & Company carries the responsibility to contribute to a company’s securities achieving fair valuation and communicate by support releasing information, handling inquiries and meeting, providing feedbacks to management, and crisis management.
PR (Public Relations) is an activity that establishes communication strategy to build and maintain a positive public perception of a company based on the analysis of internal and external environment.
As a spokesperson of the company, PR organizes broader communication with public including key opinion leaders from all industries.